KP Tissue Inc (TSE:KPT) was upgraded by equities research analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a report issued on Monday, StockTargetPrices.com reports. The brokerage currently has a C$17.00 price objective on the stock, up from their prior price objective of C$15.00. Royal Bank Of Canada’s target price would indicate a potential upside of 17.16% from the company’s previous close.
KPT has been the topic of a number of other research reports. CIBC increased their price objective on KP Tissue from C$15.00 to C$16.00 in a report on Friday, August 12th. TD Securities restated a “hold” rating and issued a C$16.00 target price on shares of KP Tissue in a research note on Friday, November 4th. Scotiabank restated an “outperform” rating and issued a C$16.50 target price on shares of KP Tissue in a research note on Thursday. Finally, Desjardins upgraded KP Tissue from a “hold” rating to a “buy” rating and upped their target price for the stock from C$13.50 to C$15.00 in a research note on Thursday, August 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of C$16.08.
KP Tissue (TSE:KPT) traded up 1.59% during trading on Monday, hitting $14.74. The company had a trading volume of 7,721 shares. The stock’s market capitalization is $134.00 million. KP Tissue has a 1-year low of $9.70 and a 1-year high of $14.84. The company’s 50 day moving average price is $14.22 and its 200-day moving average price is $13.39.
About KP Tissue